Aflibercept injections improves VA in CRVO patients

Article

Monthly intravitreal aflibercept significantly improves visual acuity (VA) in patients with macular oedema secondary to central retinal vein occlusion (CRVO), according to the latest phase of the COPERNICUS study.

Monthly intravitreal aflibercept significantly improves visual acuity (VA) in patients with macular oedema secondary to central retinal vein occlusion (CRVO), according to the latest phase of the COPERNICUS study.

Dr D.M. Brown et al., Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, conducted a multicentre, randomized, controlled trial featuring 189 patients with macular oedema secondary to CRVO. Patients were randomized to receive six monthly injections of either 2 mg intravitreal aflibercept or a sham injection.

Primary endpoint was the amount of patients who gained 15 ETDRS letters or more from baselines at the 24-week point. The additional endpoints were visual, anatomic and quality-of-life NEI VFQ-25 outcomes at weeks 24 and 52.

Of the aflibercept patients studied, 56% gained 15 letters or more, compared to 12.3% of sham patients. At week 52 this increased to 55.3% of aflibercept patients gaining 15 or more letters, compared to 30.1% of sham patients. The most common adverse effects for both groups were conjunctival haemorrhage, eye pain, reduced visual acuity and IOP.

The abstract can be found in the American Journal of Ophthalmology.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.